Choosing Anticoagulants After AFib-Related Stroke: What Does New Evidence Show?

Key Takeaways

Across 18,395 stroke survivors with atrial fibrillation pooled from six randomized controlled trials, apixaban emerged as the only blood thinner that significantly reduced both recurrent stroke and major bleeding compared with warfarin. Edoxaban was the sole agent associated with lower mortality rates. None of the newer direct-acting agents demonstrated a definitive direct superiority over one another.

The Dreaded Second Stroke

Picture a 74-year-old retired engineer, three weeks out from a stroke that stripped the strength from his right hand. The culprit was a clot dislodged from a heart in atrial fibrillation. During morning rounds, his daughter poses the question every stroke neurologist hears multiple times a week: Which blood thinner can prevent this from happening again without causing a devastating bleed in his brain?

The stakes are extraordinarily high. Even among patients already prescribed an anticoagulant, the risk of a recurrent ischemic stroke within one year of an initial event hovers around 7.0%. In this same cohort, 12.4% die within three months^[2]. In this vulnerable population, every percentage point of risk reduction is a matter of survival.

Illuminating the Question Trials Left Unanswered

Direct oral anticoagulants (DOACs) have largely supplanted warfarin as the standard of…